Overexpression of LRIG1 regulates PTEN via MAPK/MEK signaling pathway in esophageal squamous cell carcinoma

Jiang,Xiaofang; Li,Huiwu

doi:10.3892/etm.2016.3606

Overexpression of LRIG1 regulates PTEN via MAPK/MEK signaling pathway in esophageal squamous cell carcinoma

Authors:
- Xiaofang Jiang
- Huiwu Li
View Affiliations

Affiliations: Central Laboratory, Xinjiang Medical University, Urumqi, Xinjiang 830011, P.R. China, Department of Biochemistry, School of Basic Medicine, Xinjiang Medical University, Urumqi, Xinjiang 830011, P.R. China
Published online on: August 22, 2016 https://doi.org/10.3892/etm.2016.3606
Pages: 2045-2052
Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to evaluate the role of leucine-rich repeats and immunoglobulin‑like domain protein 1 (LRIG1) in the regulation of phosphatase and tensin homolog (PTEN) expression in esophageal carcinogenesis. LRIG1 was overexpressed in esophageal squamous cell carcinoma (ESCC) cell lines, and the effect of LRIG1 overexpression on the mRNA and protein expression levels of PTEN was evaluated by reverse transcription-quantitative polymerase chain reaction and western blotting. Furthermore, the effects of LRIG1 overexpression on the cell cycle distribution and apoptosis of ESCC cells were examined by flow cytometry. Various cell signaling pathway inhibitors were used to assess the effects of LRIG1 on downstream signaling in ESCC cell lines. In addition, the association between LRIG1 and PTEN expression was examined in 48 samples from patients with ESCC. LRIG1 overexpression was demonstrated to downregulate PTEN expression in ESCC cell lines, and promote their proliferation and inhibit apoptosis. In addition, LRIG1‑mediated suppression of PTEN expression was inhibited by the U0126 inhibitor, which suggests that LRIG1 may inhibit the activation of PTEN signaling molecules by triggering the mitogen‑activated protein kinase (MAPK)/MAPK kinase 1 (MEK) signaling pathway. In conclusion, the present study demonstrated that overexpression of LRIG1 significantly and adversely affected the survival of ESCC cells, and that the MAPK/MEK signaling pathway may be responsible for the repression of PTEN expression and function.

View Figures

View References

1	Nilsson J, Vallbo C, Guo D, Golovleva I, Hallberg B, Henriksson R and Hedman H: Cloning, characterization and expression of human LIG1. Biochem Biophys Res Commun. 284:31–37. 2001. View Article : Google Scholar
2	Hedman H, Nilsson J, Guo D and Henriksson R: Is LRIG1 a tumour suIs LRIG1 a tumour suppressor gene at chromosome 3p14.3? Acta Oncol. 41:352–354. 2002. View Article : Google Scholar : PubMed/NCBI
3	Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, Carraway KL III and Sweeney C: The leucine-rich repeat protein LRIG1 Is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem. 279:47050–47056. 2004. View Article : Google Scholar : PubMed/NCBI
4	Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J, Amariglio N, Henriksson R, Rechavi G, Hedman H, et al: LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J. 23:3270–3281. 2004. View Article : Google Scholar : PubMed/NCBI
5	Wang Y, Poulin EJ and Coffey RJ: LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor. Br J Cancer. 108:1765–1770. 2013. View Article : Google Scholar : PubMed/NCBI
6	Ljuslinder I, Golovleva I, Palmqvist R, Oberg A, Stenling R, Jonsson Y, Hedman H, Henriksson R and Malmer B: LRIG1 expression in colorectal cancer. Acta Oncol. 46:1118–112. 2007. View Article : Google Scholar : PubMed/NCBI
7	Thomasson M, Wang B, Hammarsten P, Dahlman A, Persson JL, Josefsson A, Stattin P, Granfors T, Egevad L, Henriksson R, et al: LRIG1 and the liar paradox in prostate cancer: A study of the expression and clinical significance of LRIG1 in prostate cancer. Int J Cancer. 128:2843–2852. 2010. View Article : Google Scholar
8	Thomasson M, Hedman H, Ljungberg B and Henriksson R: Gene expression pattern of the epidermal growth factor receptor family and LRIG1 in renal cell carcinoma. BMC Res Notes. 5:2162012. View Article : Google Scholar : PubMed/NCBI
9	Lindström AK, Ekman K, Stendahl U, Tot T, Henriksson R, Hedman H and Hellberg D: LRIG1 and squamous epithelial uterine cervical cancer: Correlation to prognosis, other tumor markers, sex steroid hormones and smoking nternational. Int J Glynecol Cancer. 18:312–317. 2008. View Article : Google Scholar
10	Guo D, Nilsson J, Haapasalo H, Raheem O, Bergenheim T, Hedman H and Henriksson R: Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors. Acta Neuropathol. 111:238–246. 2006. View Article : Google Scholar : PubMed/NCBI
11	Mak LH and Woscholski R: Targeting PTEN using small molecule inhibitors. Methods 77–78. 63–68. 2015. View Article : Google Scholar
12	Zhang H, Sun Z and Kong Y: Expression of PTEN, Her-2 and Glut-1 proteins in endometrial intraepithelial neoplasia and endometrioid. Xin Jiang Yi Ke Da Xue Xue Bao. 34:142–146. 2011.
13	Edge SB, Byrd DR and Compton CC: AJCC Cancer Staging Manual. 7th. New York: Springer; pp. 103–111. 2009
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Lee JM, Kim B, Lee SB, Jeong Y, Oh YM, Song YJ, Jung S, Choi J, Lee S, Cheong KH, et al: Cbl-independent degradation of Met: Ways to avoid agonism of bivalent Met-targeting antibody. Oncogene. 33:34–43. 2014. View Article : Google Scholar : PubMed/NCBI
16	Goldoni S, Iozzo RA, Kay P, Campbell S, McQuillan A, Agnew C, Zhu JX, Keene DR, Reed CC and Iozzo RV: A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity. Oncogene. 26:368–381. 2007. View Article : Google Scholar : PubMed/NCBI
17	Ledda F, Bieraugel O, Fard SS, Vilar M and Paratcha G: Lrig1 Is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signaling and biological responses to GDNF. J Neurosci. 28:39–49. 2008. View Article : Google Scholar : PubMed/NCBI
18	Thomasson M, Wang B, Hammarsten P, Dahlman A, Persson JL, Josefsson A, Stattin P, Granfors T, Egevad L, Henriksson R, et al: LRIG1 and the liar paradox in prostate cancer: A study of the expression and clinical significance of LRIG1 in prostate cancer. Int J Cancer. 128:2843–2852. 2011. View Article : Google Scholar : PubMed/NCBI
19	Jiang XF, Li H, Wang HJ, Li XM, Chen Y, Pang ZL, Chen HM and Li HW: Research of Lrig1 in esophageal squamous cell carcinoma. Chin J Dig. 33:123–124. 2013.
20	Ljuslinder I, Golovleva I, Henriksson R, Grankvist K, Malmer B and Hedman H: Co-incidental increase in gene copy number of ERBB2 and LRIG1 in breast cancer. Breast Cancer Res. 11:4032009. View Article : Google Scholar : PubMed/NCBI
21	Hou G, Lu Z, Liu M, Liu H and Xue L: Mutational analysis of the pten gene and its effects in esophageal squamous cell carcinoma. Dig Dis Sci. 56:1315–1322. 2011. View Article : Google Scholar : PubMed/NCBI
22	Yi W, Haapasalo H, Holmlund C, Järvelä S, Raheem O, Bergenheim AT, Hedman H and Henriksson R: Expression of leucine-rich repeats and immunoglobulin-like domains (Lrig) proteins in human ependymoma relates to tumor location, who grade and patient age. Clin Neuropathol. 28:21–27. 2009. View Article : Google Scholar : PubMed/NCBI
23	Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Bäsecke J, Stivala F, Donia M, Fagone P, et al: Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: Rationale and importance to inhibiting these pathways in human health. Oncotarget. 2:135–164. 2011. View Article : Google Scholar : PubMed/NCBI
24	Chetram MA and Hinton CV: PTEN regulation of ERK1/2 signaling in cancer. J Recept Signal Transduct Res. 32:190–195. 2012. View Article : Google Scholar : PubMed/NCBI
25	Maehama T and Dixon JE: The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 273:13375–13378. 1998. View Article : Google Scholar : PubMed/NCBI
26	Chetram MA, Don-Salu-Hewage AS and Hinton CV: ROS enhances CXCR4-mediated functions through inactivation of PTEN in prostate cancer cells. Biochem Biophys Res Commun. 410:195–200. 2011. View Article : Google Scholar : PubMed/NCBI